{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016529","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.133116+00:00","generated_at":"2026-06-09T21:25:00.196270+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024","bullets":["Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.","CEO salary set at $900,000 base (COO $750,000), target bonus 110% (COO 100%); equity grants valued at $6.2M total.","Kelderman has led Diagnostics & Genomics since 2018; previously executive at Thermo Fisher and BD.","Retention RSUs awarded to candidates Geist (~$1.05M) and Hippel (~$1.39M) vesting over two years.","Kummeth tenure: revenue grew from $311M to $1.1B, 19 acquisitions, headcount from 800 to 3,200."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016529","json":"https://secwatch.observer/filing/0001558370-23-016529.json","markdown":"https://secwatch.observer/filing/0001558370-23-016529.md","text":"https://secwatch.observer/filing/0001558370-23-016529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/tmb-20231017x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:25:00.196270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bac63bc2d","claim":"Kim Kelderman was appointed as Chief Executive Officer at BIO-TECHNE Corp.","evidence_excerpt":"Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7c43cca37d","claim":"Kim Kelderman was appointed as Chief Operating Officer at BIO-TECHNE Corp.","evidence_excerpt":"Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"9d5eda14c4","claim":"Chuck Kummeth retired as Director at BIO-TECHNE Corp.","evidence_excerpt":"Mr. Kummeth will also retire from the Board of Directors on such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b18b5e19c5","claim":"Chuck Kummeth was appointed as Senior Advisor at BIO-TECHNE Corp.","evidence_excerpt":"Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Advisor"}],"fact_type":"executive_change"},{"claim_id":"be207231c9","claim":"Kim Kelderman was appointed as Director at BIO-TECHNE Corp.","evidence_excerpt":"Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c290a70f15","claim":"Chuck Kummeth retired as Chief Executive Officer at BIO-TECHNE Corp.","evidence_excerpt":"Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}